...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Urologic oncology >Circulating mitochondrial DNA in serum: A universal diagnostic biomarker for patients with urological malignancies
【24h】

Circulating mitochondrial DNA in serum: A universal diagnostic biomarker for patients with urological malignancies

机译：血清中线粒体DNA循环：泌尿系统恶性肿瘤患者的通用诊断生物标志物

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Cell-free circulating mitochondrial DNA (mtDNA) has been proposed as universal diagnostic and prognostic biomarker in cancer patients. Patients and methods: Cell-free DNA was isolated from 1 ml serum from patients with bladder cancer (BCA, n = 84), renal cell carcinoma (RCC, n = 33), and prostate cancer (CaP, n = 23), and compared with healthy individuals (n = 79). Quantitative real-time PCR was used to analyze the levels of a 79 bp (mtDNA-79), and 220 bp (mtDNA-220) fragment of the mitochondrial specific 16S-RNA. The mitochondrial DNA integrity (mtDNA-integrity) was defined as ratio of mtDNA-220 to mtDNA-79 fragments. Results: In healthy controls, mtDNA-79 levels were increased in male volunteers; mtDNA-230 levels and mtDNA-integrity were correlated with age. Neither mtDNA levels nor mtDNA-integrity were correlated with age or gender in cancer patients. Circulating mtDNA-79 (median 8.75 × 10 6 vs. 0.43 × 10 6 copies/ml) and mtDNA-230 (8.11 × 10 6 vs. 0.27 × 10 6 copies/ml) levels were significantly increased in cancer patients and allowed sensitive (84%) and specific (97%) discrimination from healthy controls. mtDNA levels were unequally distributed among the different cancer entities (mtDNA-79: BCA 9.54 × 10 6 vs. RCC 6.69 × 10 6 vs. CaP 4.48 × 10 6 copies/ml; mtDNA-230: BCA 9.78 × 10 6 vs. RCC 6.74 × 10 6 vs. CaP 1.94 × 10 6 copies/ml). The mtDNA-integrity was increased in RCC and BCA patients compared to control subjects and CaP patients. Serum mtDNA-integrity was correlated with pathological stage in RCC and with tumor grade in BCA patients. Conclusion: Circulating mtDNA levels are associated with gender and age in healthy individuals, but not in cancer patients. Quantification of circulating mtDNA may help identify patients with urologic malignancies.
机译：目的：无细胞循环线粒体DNA（mtDNA）已被提议作为癌症患者的通用诊断和预后生物标志物。患者和方法：从1 ml血清中分离出无细胞DNA，这些血清来自患有膀胱癌（BCA，n = 33），肾细胞癌（RCC，n = 33）和前列腺癌（CaP，n = 23）的患者，以及与健康个体相比（n = 79）。实时定量PCR用于分析线粒体特异性16S-RNA的79 bp（mtDNA-79）和220 bp（mtDNA-220）片段的水平。线粒体DNA完整性（mtDNA完整性）定义为mtDNA-220与mtDNA-79片段的比率。结果：在健康对照中，男性志愿者的mtDNA-79水平升高; mtDNA-230水平和mtDNA完整性与年龄相关。癌症患者的mtDNA水平和mtDNA完整性均与年龄或性别无关。癌症患者的循环mtDNA-79（中位数为8.75×10 6 vs. 0.43×10 6个拷贝/ ml）和mtDNA-230（8.11×10 6对0.27×10 6个拷贝/ ml）的水平显着增加，并允许敏感84％）和来自健康对照的特定（97％）歧视。 mtDNA水平在不同癌症实体之间分布不均（mtDNA-79：BCA 9.54×10 6 vs. RCC 6.69×10 6 vs. CaP 4.48×10 6个拷贝/ ml; mtDNA-230：BCA 9.78×10 6 vs. RCC 6.74×10 6 vs. CaP 1.94×10 6拷贝/ ml）。与对照组和CaP患者相比，RCC和BCA患者的mtDNA完整性增加。血清mtDNA的完整性与RCC的病理分期和BCA患者的肿瘤分级有关。结论：健康个体的循环mtDNA水平与性别和年龄有关，而在癌症患者中则不相关。循环mtDNA的定量可能有助于识别患有泌尿系统恶性肿瘤的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号